Charles M. Perou

Founder at GeneCentric Therapeutics, Inc.

Consumer Services

Health Technology

Profile

Charles M.
Perou is the founder of GeneCentric Therapeutics, Inc. which was founded in 2011.
He is currently a Member at The University of North Carolina at Charlotte since 2000.
Dr. Perou holds a doctorate degree from the University of Utah and an undergraduate degree from Bates College.

Charles M. Perou active positions

Companies	Position	Start
GeneCentric Therapeutics, Inc. GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC.	Founder	2010-12-31
The University of North Carolina at Charlotte	Corporate Officer/Principal	1999-12-31

All active positions of Charles M. Perou

Training of Charles M. Perou

Bates College	Undergraduate Degree
University of Utah	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Charles M. Perou's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
GeneCentric Therapeutics, Inc. GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC.	Health Technology